You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

249 Results
Drug
Other Name(s): Columvi®
Jan 2025
Drug
Other Name(s): Epkinly™
Jan 2025
Guidelines and Advice
Nov 2024
Cancer screening can find abnormal cell changes before they become cancer or cancer at an early stage, when treatment has a better chance of working...
Drug
Other Name(s): Iressa®
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria
Apr 2025
Guidelines and Advice
Status: Current
ID: GL 20-2
Version: 2
Updated
Apr 2025
Guidelines and Advice
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer
May 2025

Pages